Medication Abortion and Family Physicians’ Scope of Practice

References

1. ↵
   Alan Guttmacher Institute [homepage on the Internet]. New York: Alan Guttmacher Institute; c2003. [updated 2003 May 7]. State facts about abortion; [about 1 screen]. Available from: http://www.agi-usa.org/pubs/sfaa.html.
2. ↵
   Finer LB, Henshaw HK. Abortion incidence in the United States in 2000. Perspect Sexual Reprod Health 2003; 35: 16–24.

   OpenUrl
3. ↵
   Lerner S. Abortion’s new choice. Village Voice 2000 Oct 4; Features:43–8.
4. Koenig JD, Tapias MD, Hoff T, Stewart FH. Are US health professionals likely to prescribe mifepristone or methotrexate? J Am Med Women’s Assoc 2000; 55: 155–60.
5. Joffe C. Medical abortion in social context. Am J Obstet Gynecol 2000; 183: 10–5.

   OpenUrl
6. Henry J. Kaiser Family Foundation. A National Survey: views of women’s health care providers on medical abortion. Menlo Park (CA): Kaiser Family Foundation; 2000.
7. ↵
   Joffe C. Roe v. Wade at 30: What are the prospects for abortion provision. Perspect Sexual Reprod Health 2003; 35: 29–33.
8. ↵
   Boonstra H. Mifepristone in the United States: status and future. The Guttmacher Report on Public Policy 2002;5:4–7. Available from http://www.guttmacher.org/pubs/tgr/05/3/gr050304.html
9. ↵
   American Academy of Family Physician [homepage on the Internet]. Leawood (KS): American Academy of Family Physicians; c2004 [updated 2005; cited 2004 Aug 13]. AAFP policy and advocacy: family medicine; [about 2 screens]. Available from: http://www.aafp.org/x6809.xml.
10. ↵
    Fryer GE, Green LA, Dovey SM, Phillips RI Jr. The United States relies on family physicians unlike any other specialty. Am Fam Physician 2001; 63: 1669.

    OpenUrlPubMedWeb of Science
11. ↵
    Henshaw HK, Finer LB. The accessibility of abortion services in the United States, 2001. Perspect Sexual Reprod Health 2003; 35: 6–15.

    OpenUrl
12. ↵
    Westhoff C, Marks F, Rosenfield A. Residency training in contraception, sterilization and abortion. Obstet Gynecol 1993; 81: 311–4.

    OpenUrlPubMedWeb of Science
13. Grimes DA. Clinicians who provide abortions: the thinning ranks. Obstet Gynecol 1992; 80: 719–23.

    OpenUrlPubMedWeb of Science
14. Steinauer J, DePinerest T, Robert AM, Wesfall J, Darney P. Training family practice residents in abortion and other reproductive health care: a nationwide survey. Fam Plann Perspect 1997; 29: 222–7.

    OpenUrlCrossRefPubMedWeb of Science
15. ↵
    Gold M, Luks D, Anderson MR. Medical options for early pregnancy termination. Am Fam Physician 1997; 56: 533–8.

    OpenUrlPubMed
16. ↵
    Lichtenberg ES, Paul M, Jones H. First trimester surgical abortion practices: a survey of National Abortion Federation members. Contraception 2001; 64: 345–52.

    OpenUrlCrossRefPubMedWeb of Science
17. ↵
    Approval letter Mifeprex (mifepristone) tablets [letter on the Internet]. Bethesda (MD): Food and Drug Administration; c2000 [posted 2000 Sept 28; cited 2004 Aug 13]. Available from: http://www.fda.gov/cder/foi/appletter/2000/20687appltr.htm.
18. ↵
    Allen RH, Westhoff C, De Nonno L, Fielding SL, Schaff EA. Curettage after mifepristone-induced abortion: frequency, timing, and indications. Obstet Gynecol 2001; 98: 101–6.

    OpenUrlCrossRefPubMed
19. Schaff EA, Stadalius LS, Eisinger SH, Frank P. Vaginal misoprostol administered at home after mifepristone for abortion. J Fam Pract 1997; 44: 353–60.

    OpenUrlPubMedWeb of Science
20. Prine L, Lesnewski R, Berley N, Gold M. Medical abortion outcomes in four family practices. J Am Board Fam Pract 2003; 16: 290–5.

    OpenUrlAbstract/FREE Full Text
21. ↵
    Newhall EP, Winikoff B. Abortion with mifepristone and misoprostol: regimens, efficacy, acceptability and future directions. Am J Obstet Gynecol 2000; 183 Suppl 2: S44–53.

    OpenUrl
22. ↵
    Stewart FH, Shields WC, Hwang AC. Presenting health risks honestly: mifepristone, a case in point. Contraception 2004; 69: 177–8.

    OpenUrlPubMed
23. Elam-Evans LD, Strauss LT, Herndon J, Parker WY, Whitehead S, Berg CJ. Abortion surveillance—United States, 1999. MMWR Surveill Summ 2002; 51: 1–9, 11–28.

    OpenUrlPubMed
24. Chang J, Elam-Evans LD, Berg CJ, et al. Pregnancy-related mortality surveillance—United States, 1991–1999. MMWR Surveill Summ 2003; 52: 1–14.

    OpenUrlPubMed
25. Morrison H. Sildenafil (Viagra): cardiac risks. CMAJ 2000; 163: 86–7, 90–1.
26. ↵
    Wysowski DK, Farinas E, Swartz L. Comparison of reported and expected deaths in sildenafil (Viagra) users. Am J Cardiol 2002; 89: 1331–4.

    OpenUrlCrossRefPubMedWeb of Science
27. Egan R, Pomeranz H. Sildenafil (Viagra) associated anterior ischemic optic neuropathy. Arch Opthalmol 2000; 118: 291–2.

    OpenUrl
28. Cohen JS. Comparison of FDA reports of patient deaths associated with sildenafil and with injectable alprostadil. Ann Pharmacother 2001; 35: 285–8.

    OpenUrlAbstract/FREE Full Text